Abbott Laboratories AI Adoption Tracker
Last updated: August 9, 2026
Overview
Abbott Laboratories has emerged as a significant player in healthcare AI, strategically integrating artificial intelligence across its medical devices and diagnostics portfolios [1][2]. The company launched a comprehensive AI strategy with published Responsible AI principles emphasizing safety, transparency, and fairness [3]. Abbott's AI initiatives span multiple therapeutic areas, including the FreeStyle Libre ecosystem for diabetes management, AI-powered cardiac imaging through partnerships like iCardio.ai for electrophysiology applications [4], and the Ultreon 2.0 software for cardiovascular interventions using optical coherence tomography [5]. The company's AI approach focuses on creating interconnected platforms that span the full patient journey, from continuous monitoring and diagnosis to therapeutic intervention and follow-up [2]. Most recently, Abbott unveiled Libre Assist in January 2026, a generative AI feature within the Libre app that predicts glucose impact of foods before eating and provides personalized meal guidance [6].
- [1] Abbott's AI Strategy: Analysis of AI Dominance in Medical Devices, Healthcare
- [2] Abbott's AI Strategy: Analysis of AI Dominance in Medical Devices, Healthcare
- [3] Abbott and responsible AI
- [4] Abbott, iCardio.ai partner on AI for electrophysiology imaging
- [5] Artificial Intelligence at Abbott – Two Current Use-Cases
- [6] Abbott's new Libre Assist app feature tackles a top need for people living with diabetes
AI Maturity Index
Radar Comparison
Peer Comparison: Abbott Laboratories vs healthcare
Based on 66 companies in sector
| Dimension | Abbott Laboratories | Sector Avg | Diff |
|---|---|---|---|
| Adoption | 3.0 | 3.7 | -0.7 |
| Proficiency | 3.0 | 3.5 | -0.5 |
| Impact | 3.0 | 3.6 | -0.6 |
| Overall | 3.0 | 3.6 | -0.6 |
AI Hiring Signals
Abbott Laboratories Job Postings Analysis
Tech vs Non-Tech AI Requirements
Non-tech AI adoption exceeds tech roles - strong org-wide AI fluency signal
Top Departments by AI Mention Rate
Analysis
Abbott shows minimal AI hiring emphasis with only 1.4% of job postings mentioning AI. Surprisingly, non-tech roles show higher AI expectations (1.8%) than tech roles (0%), suggesting selective AI integration in specific operational areas rather than broad technical AI capabilities.
View Sample Job Postings (5 sources)
Key Metrics
AI Initiatives
Libre Assist
January 2026
Generative AI feature within the Libre app that predicts how foods will affect glucose levels before eating
Uses AI to identify food ingredients from photos or text descriptions, provides color-coded glucose impact ratings (green/yellow/orange), offers personalized meal guidance, and confirms actual glucose response using FreeStyle Libre CGM data. Available at no additional cost within the Libre app.
LARALAB Acquisition
October 2025
Acquisition of Munich-based AI-powered cardiac imaging company
Abbott acquired LARALAB to expand heart.ai technology, a cloud-based cardiac imaging platform that empowers clinicians in planning structural heart interventions. LARALAB's platform is the first fully automated AI platform for comprehensive CT analysis across structural heart applications including TAVR, TMVR, and TTVR.
iCardio.ai Partnership
September 2024
Collaboration to develop AI applications for electrophysiology imaging devices
Partnership with Los Angeles-based iCardio.ai to accelerate AI integration into Abbott's electrophysiology imaging product line, specifically the EnSite X cardiac mapping system using 2D intracardiac echo (ICE) images. iCardio.ai leverages a database of over 200 million images.
AI Governance Framework
2024
Published Responsible AI principles and governance structure
Abbott established five key AI principles: Responsible, Safe, Transparent, Fair, and Impactful. The company created a Data Use & Ethics Board and published a comprehensive framework emphasizing scientific standards, human oversight, representative datasets, and positive impact on people's health.
Frequently Asked Questions
Libre Assist is a generative AI feature within Abbott's Libre app that predicts how foods will affect glucose levels before eating. Users take a photo or enter text description of their meal, the AI identifies ingredients and provides a color-coded glucose impact rating (green for minor, yellow for moderate, orange for major impact), along with personalized meal tips. After eating, it shows actual glucose data from the FreeStyle Libre sensor to confirm the prediction.
Abbott uses AI in cardiovascular care through multiple applications: the Ultreon 2.0 software combines optical coherence tomography with AI for real-time vessel imaging during procedures; partnerships with iCardio.ai bring AI to electrophysiology imaging; and the acquisition of LARALAB expands AI-powered cardiac imaging for structural heart interventions including TAVR procedures.
Abbott's responsible AI approach is built on five key principles: Responsible (intentional use with scientific standards), Safe (protecting quality and safety), Transparent (clear communication about AI use), Fair (representative datasets to minimize bias), and Impactful (making life better for humans). The company has established a Data Use & Ethics Board to oversee implementation.
Libre Assist is available at no additional cost within the Libre app for users of Abbott's FreeStyle Libre continuous glucose monitoring systems. It launched in January 2026 for people living with diabetes in the U.S. Users need a compatible smartphone and must download the Libre app to access the feature.
Abbott's strategy focuses on creating interconnected, data-rich ecosystems that span the full patient journey from monitoring to treatment. The company has strategically pivoted toward data-intensive business segments (Medical Devices and Diagnostics) and emphasizes closed-loop, patient-centric AI applications rather than standalone AI tools, differentiating it from competitors' approaches.
In Application
| Application | Vendor | Use Case |
|---|---|---|
| Generative AI | Internal development | Food identification and glucose impact prediction in Libre Assist feature |
| Machine Learning Algorithms | iCardio.ai partnership | Echocardiography analysis and cardiac imaging automation |
| Deep Learning | LARALAB acquisition | CT analysis for structural heart procedures and procedural planning |
Sources
Abbott's AI Strategy: Analysis of AI Dominance in Medical Devices, Healthcare
Abbott's AI Strategy: Analysis of AI Dominance in Medical Devices, Healthcare
Abbott and responsible AI
Abbott, iCardio.ai partner on AI for electrophysiology imaging
Artificial Intelligence at Abbott – Two Current Use-Cases
Abbott's new Libre Assist app feature tackles a top need for people living with diabetes
Related Companies
About AI Tracker
AI Tracker is a research project by Larridin, the AI execution intelligence platform.
Methodology: We analyze earnings calls, press releases, partnership announcements, and product documentation. All assessments are based solely on publicly available information—no private customer data is used.
Maturity Scoring: Each dimension is rated on a 4-tier scale (Nascent → Emerging → Scaling → Leading) based on evidence from public sources. Industry averages are computed as the median across all tracked companies in the sector.